Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

Abstract Objective To explore whether a prime-boost vaccination strategy, i.e., a dose of pneumococcal conjugate vaccine (PCV) and a dose of 23-valent polysaccharide vaccine (PPV23), enhances antibody response compared to single PCV dose in patients with inflammatory rheumatic diseases treated with...

Full description

Bibliographic Details
Main Authors: Per Nived, Göran Jönsson, Bo Settergren, Jon Einarsson, Tor Olofsson, Charlotte Sværke Jørgensen, Lillemor Skattum, Meliha C. Kapetanovic
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Arthritis Research & Therapy
Subjects:
Pneumococcal conjugate vaccine
Rituximab
Abatacept
Synthetic disease-modifying antirheumatic drugs
Online Access:http://link.springer.com/article/10.1186/s13075-020-2124-3

Internet

http://link.springer.com/article/10.1186/s13075-020-2124-3

Similar Items